As the crisis of antibiotic resistant gonorrhea becomes even more urgent, last week the CDC released a Notice of Funding…
The CDC funding reflects the increasing pressure faced by public and private labs to build out laboratory capabilities for culture diagnostics. Healthcare is confronting an explosive growth in antibiotic-resistant infections. Culture testing is critical to conduct microbial sensitivity/susceptibility analysis with anti-bacterial agents. Successful treatment depends on appropriate testing.
According to the CDC NOFO, “these objectives will be met through implementing detection and response services at local, national, and regional levels; evaluating and continually improving implementation; ……enhancing laboratory capacity at key participating labs; and actively facilitating learning to other partners in the country/region.”
The CDC states “Fighting emerging infections, antibiotic resistance…this Notice of Funding Opportunity (NOFO) will enhance detection and response to emerging infectious disease threats in healthcare facilities..”
A significant portion of the $10 Million will be awarded to applicants who propose to expand testing capacity and improve laboratory staff ability to detect and share data on emerging antimicrobial resistant Neisseria Gonorrhoeae
According to the Center for Disease Control and Prevention (CDC), Neisseria Gonorrhoeae poses one of the most urgent threats of antibiotic resistance infections in the United States and the world.
There is only one class of antibiotics that is currently deemed an effective treatment for this devastating disease.
Recipients of this new CDC funding are encouraged to build and sustain strategic partnerships with organizations and companies that can support the implementation of a recipient’s proposed work plan.
Biomed Diagnostics has solved the challenges of culture diagnostics and testing for Neisseria gonorrhea.
InTray® GC has been recommended by the CDC as superior for transport and recovery of Neisseria gonorrhoeae
For over 10 years, Biomed Diagnostic's has partnered with clinical laboratories and health care agencies worldwide in the fight against AMR GC. Engineered for ease of use, in Vitro transport and culture, the InTray GC® is a prepared culture device, specific and selective for qualitative detection of oral, rectal and genito-urethral Neisseria gonorrhoeae. It is an essential tool for AMR diagnostics.
Embedded C02 tablet, InTray GC does not require an expensive C02incubator, and there are no requirements for replating of the culture for detection. Inoculate the InTray, seal, and observe for microbial growth and color change within 24 hours. Isolates may be easily harvested for molecular or genetic analysis.